Dispute Resolution: Ardelyx Eyes Tenapanor Resubmission Following Successful Appeal To FDA

Office of New Drugs grants company’s appeal of complete response letter for tenapanor in dialysis patients, marking a rare sponsor victory through the agency’s formal dispute resolution process; new drug application resubmission is targeted for first half of 2023.

Chess pieces
Ardelyx prevailed in its appeal of a complete response letter. • Source: Shutterstock

A rare sponsor victory on an appeal of a complete response letter for Ardelyx Inc.’s phosphate absorption inhibitor Xphozah (tenapanor) could embolden other sponsors to pursue dispute resolution when a US Food and Drug Administration review division concludes a drug is not approvable based upon currently available evidence.

On 29 December, Ardelyx announced that the Office of New Drugs (OND) granted its appeal of the June 2021 CRL...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet